VPD’s strategy is to create, invest in, and manage a portfolio of “project-focused companies,” each of which contains a single drug candidate acquired from a third party. VPD designs and executes the clinical development program for each of these drug candidates. VPD acquires rights to individual therapeutic drug candidates from biotechnology companies, pharmaceutical companies and academia, and invests in their development through clinical proof-of-concept (generally demonstration of human safety and efficacy in phase 2a trials). Following proof-of-concept, VPD seeks to sell each drug asset to a major pharmaceutical company. There is a robust demand by pharmaceutical acquirers for products with key human clinical data. Our model provides partners with a compelling alternative strategy for the development of their drug candidates. By partnering with VPD, the owner of a drug candidate can achieve the funding needed to take the drug candidate to clinical proof-of-concept while accessing a world-class team to design and oversee the development program. The contributor of the drug candidate receives equity in the company created to house its drug program and benefits from the ultimate financial upside upon clinical success and sale of that company to a pharmaceutical company. The Velocity model is much more efficient than traditional company-based drug development because it avoids the cost and time of building a separate management team and infrastructure around each program.
View Top Employees from Velocity Pharmaceutical Development, LLCWebsite | http://www.vpd.net |
Revenue | $3 million |
Employees | 2 (2 on RocketReach) |
Founded | 2011 |
Address | 400 Oyster Point Boulevard Suite # 202, South San Francisco, California 94080, US |
Phone | (650) 745-8179 |
Technologies |
JavaScript,
HTML,
PHP
+15 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Manufacturing General, Biotechnology, World-Class Drug Development Team, Manufacturing, Science and Engineering, Short Holding Period: Average of 3 Years, Business Development, Creating Project-Focused Companies, Pharmaceutical, Investing in Drug Candidates Through Proof of Concept, Health Care, We Build Drugs, Not Companies |
Web Rank | 14 Million |
Keywords | Natrecor Nooshin, Velocity Pharmaceutical Development, Andy Perlman Genentech, Jim Larrick |
Competitors | India Pvt. Ltd, Menlo Therapeutics Inc., Merz Therapeutics, Salix Pharmaceuticals, Tioga Pharmaceuticals, Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular Velocity Pharmaceutical Development, LLC employee's phone or email?
The Velocity Pharmaceutical Development, LLC annual revenue was $3 million in 2024.
2 people are employed at Velocity Pharmaceutical Development, LLC.
Velocity Pharmaceutical Development, LLC is based in South San Francisco, California.
The NAICS codes for Velocity Pharmaceutical Development, LLC are [32541, 32, 3254, 325].
The SIC codes for Velocity Pharmaceutical Development, LLC are [28, 283].